A new observational study suggests that initiating SGLT-2 inhibitors within a month of severe kidney injury could reduce the risk of advanced kidney dysfunction in adults with type 2 diabetes, highlighting a potential window for therapeutic intervention.
A new analysis published in JAMA Network Open suggests that some adults with type 2 diabetes may do better if an SGLT-2 inhibitor is started within 30 days of leaving hospital after a serious kidney injury rather than waiting longer.
The study looked at patients who had acute kidney injury severe enough to require dialysis during admission, then recovered enough to stop dialysis after discharge. Researchers from National Taiwan University Hospital examined de-identified records from the TriNetX Global Collaborative Network and compared people who began treatment early with those who started between 31 and 90 days after discharge.
Among the 4,406 adults identified, the main comparison involved 1,912 patients in each group after statistical matching. Serious kidney outcomes were recorded in 3.9% of the early-treatment group, compared with 6.2% of those who started later. The difference was driven mainly by fewer cases of very advanced kidney dysfunction, while the need to restart dialysis was not significantly different between the groups.
Safety also appeared broadly similar over six months of follow-up. Recorded problems such as urinary tract infections, diabetic ketoacidosis, heart failure, low blood sugar, excess fluid loss and fungal genital or urinary infections were comparable in both groups. Even so, the findings do not prove that earlier treatment caused the better outcomes, because the study was observational rather than a randomised trial.
The result fits with a wider body of evidence showing that SGLT-2 inhibitors, first developed to lower blood sugar, can also protect the kidneys and heart. A review in the National Library of Medicine described the drugs’ long-term renal benefits, including an initial fall in estimated glomerular filtration rate followed by slower kidney decline, while a Circulation analysis of large placebo-controlled trials stressed that the timing of cardio-renal protection can vary by patient group. The new study adds to that debate by suggesting that the weeks soon after severe kidney injury may be a crucial window for treatment, although further trials will be needed before any firm clinical recommendation can be made.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
